MCID: PRR002
MIFTS: 52

Pure Red-Cell Aplasia

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Pure Red-Cell Aplasia

MalaCards integrated aliases for Pure Red-Cell Aplasia:

Name: Pure Red-Cell Aplasia 12 14 69
Pure Red Cell Aplasia 12 72 49
Primary Red Cell Aplasia 12
Red-Cell Aplasia, Pure 41
Red-Cell Aplasia Pure 51
Red Cell Hypoplasia 12
Prca 49

Classifications:



External Ids:

Disease Ontology 12 DOID:1340
MeSH 41 D012010
NCIt 46 C34974
UMLS 69 C0034902

Summaries for Pure Red-Cell Aplasia

NIH Rare Diseases : 49 Pure red cell aplasia (PRCA) is a rare condition that affects the bone marrow. Bone marrow contains stem cells which develop into the red blood cells that carry oxygen through the body, the white blood cells that fight infections, and the platelets that help with blood clotting. In people with PRCA, the bone marrow makes a reduced number of red blood cells (called anemia). As a result, affected people may experience fatigue, lethargy, and pale skin. PRCA has many different causes. A rare congenital form of PRCA, called Diamond Blackfan syndrome, is an inherited condition that is also associated with other physical abnormalities. PRCA can also be due to certain medications, infections, pregnancy, renal failure, and conditions such as thymomas, autoimmune disease (such as systemic lupus erythematosus), cancers of the blood, and solid tumors. In many cases, the cause of the condition is unknown (idiopathic). The treatment of PRCA aims to address the underlying cause of the condition and relieve the associated signs and symptoms. Last updated: 4/21/2016

MalaCards based summary : Pure Red-Cell Aplasia, also known as pure red cell aplasia, is related to large granular lymphocyte leukemia and chronic graft versus host disease. An important gene associated with Pure Red-Cell Aplasia is EPO (Erythropoietin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Iron and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Pure red cell aplasia (PRCA) or erythroblastopenia refers to a type of anemia affecting the precursors... more...

Related Diseases for Pure Red-Cell Aplasia

Diseases related to Pure Red-Cell Aplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Related Disease Score Top Affiliating Genes
1 large granular lymphocyte leukemia 31.3 IL2RA STAT3
2 chronic graft versus host disease 30.7 ALB IL2RA
3 t-cell large granular lymphocyte leukemia 30.5 IL2 STAT3
4 chronic kidney failure 30.4 ALB EPO TF
5 b-cell expansion with nfkb and t-cell anergy 30.3 IL2 IL2RA TRB
6 immune suppression 30.3 IL2 STAT3
7 marasmus 30.2 ALB TF
8 kwashiorkor 30.2 ALB TF
9 hematopoietic stem cell transplantation 30.1 HLA-A HLA-B IL2
10 celiac disease 1 30.1 ALB HLA-A IL2
11 hemosiderosis 29.8 EPO TF
12 sclerosing cholangitis 29.7 ALB HLA-B HLA-DRB1
13 cholangitis 29.7 ALB HLA-B HLA-DRB1
14 graft-versus-host disease 29.5 HLA-A HLA-B HLA-DRB1 IL2
15 autoimmune disease 28.7 HLA-B HLA-DRB1 IL2 IL2RA STAT3
16 aplastic anemia 28.3 EPO HLA-A HLA-B HLA-DRB1 IL2 RPS17
17 acquired pure red cell aplasia 12.9
18 transient erythroblastopenia of childhood 12.2
19 diamond-blackfan anemia 11.6
20 thymoma, familial 10.7
21 thymoma 10.7
22 leukemia 10.7
23 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
24 hemolytic anemia 10.6
25 hepatitis 10.6
26 lymphoma 10.6
27 lupus erythematosus 10.6
28 systemic lupus erythematosus 10.6
29 anemia, autoimmune hemolytic 10.6
30 leukemia, chronic lymphocytic 2 10.5
31 leukemia, chronic lymphocytic 10.5
32 leukemia, b-cell, chronic 10.5
33 myelodysplastic syndrome 10.4
34 splenic disease 10.4 ALB EPO
35 anteroseptal myocardial infarction 10.4 ALB HLA-DRB1
36 myasthenia gravis 10.4
37 myasthenia gravis congenital 10.4
38 rheumatoid factor-negative juvenile idiopathic arthritis 10.4 HLA-DRB1 IL2RA
39 hepatitis c 10.4
40 fetal erythroblastosis 10.4 ALB EPO
41 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.3
42 thrombocytopenia 10.3
43 rh isoimmunization 10.3 ALB EPO
44 hemorrhagic fever 10.3 ALB HLA-DRB1
45 autoimmune enteropathy 10.3 IL2RA STAT3
46 autoimmune lymphoproliferative syndrome, type v 10.3
47 hepatitis a 10.3
48 renal hypertension 10.3 ALB EPO
49 berylliosis 10.3 HLA-DRB1 IL2
50 recurrent respiratory papillomatosis 10.3 HLA-DRB1 IL2

Graphical network of the top 20 diseases related to Pure Red-Cell Aplasia:



Diseases related to Pure Red-Cell Aplasia

Symptoms & Phenotypes for Pure Red-Cell Aplasia

GenomeRNAi Phenotypes related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

25 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.74 HLA-A HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.74 RPS17
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.74 HLA-B HLA-A
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.74 HLA-A HLA-B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.74 HLA-B HLA-A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.74 RPS17
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.74 RPS17
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.74 HLA-B HLA-A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.74 HLA-B HLA-A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.74 RPS17
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.74 HLA-B HLA-A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.74 RPS17
13 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.74 RPS17
14 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.74 HLA-A HLA-B RPS17
15 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.74 HLA-A HLA-B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.74 RPS17

Drugs & Therapeutics for Pure Red-Cell Aplasia

Drugs for Pure Red-Cell Aplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Darbepoetin alfa Approved, Investigational Phase 4,Phase 2 209810-58-2, 11096-26-7
4
Deferasirox Approved, Investigational Phase 4,Phase 3,Phase 2 201530-41-8 5493381
5
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
6
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
7 Antibodies Phase 4,Phase 3,Phase 2
8 Epoetin alfa Phase 4,Phase 3,Phase 2 113427-24-0
9 Hematinics Phase 4,Phase 3,Phase 2
10 Immunoglobulins Phase 4,Phase 3,Phase 2
11 Liver Extracts Phase 4
12 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
15 Chelating Agents Phase 4,Phase 3,Phase 2
16 Iron Chelating Agents Phase 4,Phase 3,Phase 2
17 Micronutrients Phase 4,Phase 3
18 Trace Elements Phase 4,Phase 3
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
21
Cyclophosphamide Approved, Investigational Phase 2, Phase 3, Phase 1 50-18-0, 6055-19-2 2907
22
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
23
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
25
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
26
Busulfan Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 55-98-1 2478
27
Fludarabine Approved Phase 2, Phase 3, Phase 1, Early Phase 1 21679-14-1, 75607-67-9 30751
28
Vidarabine Approved, Investigational Phase 2, Phase 3 24356-66-9 21704 32326
29
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 216503-57-0
30
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
31
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
32 tannic acid Approved, Nutraceutical Phase 3,Phase 2
33 Orange Approved, Nutraceutical Phase 3
34 Alkylating Agents Phase 2, Phase 3, Phase 1
35 Antilymphocyte Serum Phase 2, Phase 3, Phase 1
36 Antirheumatic Agents Phase 2, Phase 3, Phase 1
37 Antiemetics Phase 3,Phase 2
38 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
40 Autonomic Agents Phase 3,Phase 2
41 Calcineurin Inhibitors Phase 3,Phase 2
42 Cyclosporins Phase 3,Phase 2,Phase 1
43 Dermatologic Agents Phase 3,Phase 2
44 Gastrointestinal Agents Phase 3,Phase 2
45 glucocorticoids Phase 3,Phase 2,Phase 1
46 Hormone Antagonists Phase 3,Phase 2,Phase 1
47 Hormones Phase 3,Phase 2,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
49 Methylprednisolone acetate Phase 3,Phase 2
50 Methylprednisolone Hemisuccinate Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 64)

# Name Status NCT ID Phase Drugs
1 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4
2 A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment Completed NCT00211042 Phase 4
3 Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin Completed NCT00210951 Phase 4
4 A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins Completed NCT00211029 Phase 4
5 A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa Completed NCT00211068 Phase 4 No intervention
6 Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure Completed NCT00391287 Phase 4
7 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropo Completed NCT00773513 Phase 4 Darbepoetin Alfa;Epoetin Alfa;Epoetin Beta;methoxy polyethylene glycol-epoetin beta
8 Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Completed NCT00673608 Phase 4 deferasirox
9 Sirolimus Treatment for Refractory PRCA Recruiting NCT03364764 Phase 4 Sirolimus
10 A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies Withdrawn NCT00210977 Phase 4 No intervention
11 Efficacy and Safety Study of GerEPO Completed NCT00229099 Phase 3 GerEPO
12 Iron Sucrose in Stage 3/4 Kidney Disease Completed NCT00202345 Phase 3 Iron sucrose
13 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed NCT00235391 Phase 3 Deferasirox
14 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
15 Stem Cell Transplant for Hemoglobinopathy Active, not recruiting NCT00176852 Phase 2, Phase 3 Busulfan, Fludarabine, ATG, TLI;Busulfan, Cyclophosphamide, ATG, GCSF;Campath, Fludarabine, Cyclophosphamide
16 Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment Terminated NCT01288131 Phase 3 Cyclosporine combine with mycophenolate mofetil;Cyclophosphamide + pred
17 A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer Terminated NCT00246597 Phase 3 epoetin alfa
18 L-leucine in Diamond Blackfan Anemia Patients Unknown status NCT02386267 Phase 2 L-leucine
19 Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Completed NCT00229619 Phase 2 Rituximab
20 Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease Completed NCT00314795 Phase 2 peginesatide
21 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
22 A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Completed NCT01044186 Phase 2 ICL670
23 Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia Completed NCT00011505 Phase 2 G-CSF
24 Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remi Completed NCT00305708 Phase 1, Phase 2 busulfan;fludarabine phosphate
25 Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders Completed NCT00301834 Phase 2 busulfan;cyclosporine;fludarabine phosphate;methotrexate;methylprednisolone
26 Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias Completed NCT00061763 Phase 2 Deferasirox
27 Medical Treatment for Diamond Blackfan Anemia Completed NCT00001749 Phase 2 Antithymocyte globulin;Cyclosporine
28 Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor Recruiting NCT03214354 Phase 2 Alemtuzumab;Sirolimus
29 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure Recruiting NCT02105766 Phase 1, Phase 2 Alemtuzumab;Sirolimus;Cyclophosphamide;Pentostatin;Radiotherapy
30 Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia Recruiting NCT01464164 Phase 1, Phase 2 Sotatercept;Sotatercept with prednisone boost
31 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
32 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Recruiting NCT01174108 Phase 2
33 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Recruiting NCT00003838 Phase 2
34 Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias Recruiting NCT00061568 Phase 2 Alemtuzumab (Campath );Sirolimus (Rapamune )
35 Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia Active, not recruiting NCT01362595 Phase 1, Phase 2 leucine
36 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
37 Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies Suspended NCT01419704 Phase 1, Phase 2
38 A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure Terminated NCT00001962 Phase 2 Daclizumab
39 The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias Terminated NCT00472433 Phase 2 Alemtuzumab
40 A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002) Terminated NCT00968617 Phase 2 MK2578;MK2578;MK2578;Comparator: darbepoetin alfa
41 A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12) Terminated NCT00924781 Phase 2 MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline;MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline;MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
42 Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Terminated NCT02512679 Phase 2 Cyclophosphamide Dose Level 1;Cyclophosphamide Dose Level 2;Cyclophosphamide Dose Level 3;Cyclophosphamide Dose Level 4
43 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs Terminated NCT00957931 Phase 2
44 BMT Abatacept for Non-Malignant Diseases Recruiting NCT01917708 Phase 1 Abatacept
45 Human Placental-Derived Stem Cell Transplantation Active, not recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
46 Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia Terminated NCT01034592 Phase 1 Lenalidomide
47 Identifying Characteristics of Bone Marrow Failure Syndromes Unknown status NCT00315419
48 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
49 Multi-Center Study of Iron Overload: Survey Study (MCSIO) Unknown status NCT01913548
50 Multi-Center Study of Iron Overload: Pilot Study Unknown status NCT01114776

Search NIH Clinical Center for Pure Red-Cell Aplasia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: red-cell aplasia, pure

Genetic Tests for Pure Red-Cell Aplasia

Anatomical Context for Pure Red-Cell Aplasia

MalaCards organs/tissues related to Pure Red-Cell Aplasia:

38
Bone, Bone Marrow, Kidney, T Cells, Skin, Liver, B Cells

Publications for Pure Red-Cell Aplasia

Articles related to Pure Red-Cell Aplasia:

(show top 50) (show all 641)
# Title Authors Year
1
Rational management approach to pure red cell aplasia. ( 29217782 )
2018
2
Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation. ( 29079126 )
2018
3
Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2. ( 28230570 )
2017
4
Trend and treatment patterns of aplastic anemia in Korea, pure red cell aplasia and myelodysplastic syndrome in Korea: a nation-wide analysis. ( 28664500 )
2017
5
Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature. ( 28924112 )
2017
6
Pure Red Cell Aplasia Due to Parvovirus B19: Erythropoietin-Resistant Anemia in a Pediatric Kidney Recipient. ( 28387173 )
2017
7
Cyclosporin A Reversed Chemoresistance of a Patient with Pure Red Cell Aplasia Secondary to Thymoma. ( 28739760 )
2017
8
T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia. ( 29296951 )
2017
9
A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma. ( 28872489 )
2017
10
Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients. ( 28042550 )
2017
11
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
12
Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. ( 28543448 )
2017
13
Pure red cell aplasia and myasthenia gravis: a patient having both autoimmune conditions in the absence of thymoma. ( 28893803 )
2017
14
Pure Red Cell Aplasia Associated with Good Syndrome. ( 28382272 )
2017
15
Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review. ( 28182355 )
2017
16
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib. ( 27756158 )
2017
17
Use of Nandrolone Decanoate in Treatment of Pure Red Cell Aplasia Secondary to Diclofenac Administration: A Case Report. ( 28750791 )
2017
18
Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation. ( 28488966 )
2017
19
Successful treatment of tacrolimus-related pure red cell aplasia and autoimmune hemolytic anemia with rituximab in a pediatric cardiac transplant patient. ( 28598573 )
2017
20
Pure red cell aplasia due to azathioprine therapy for Crohn's disease. ( 26997730 )
2016
21
Coombs-negative Autoimmune Hemolytic Anemia Followed by Anti-erythropoetin Receptor Antibody-associated Pure Red Cell Aplasia: A Case Report and Review of Literature. ( 26935373 )
2016
22
Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. ( 26981948 )
2016
23
Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. ( 27311084 )
2016
24
Pure red cell aplasia induced by epoetin zeta. ( 27478604 )
2016
25
Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia. ( 26968551 )
2016
26
Pure Red Cell Aplasia and Autoimmune Hemolytic Anemia Sequentially Occurring in a Patient with Large Granular T-lymphocytic Leukemia. ( 27250059 )
2016
27
Pure red cell aplasia caused by parvovirus B19 in a heart transplant recipient. ( 27648265 )
2016
28
Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine. ( 28509169 )
2016
29
Moderate-dose cyclophosphamide in the treatment of relapsed/refractory T-cell large granular lymphocytic leukemia-associated pure red cell aplasia. ( 27077768 )
2016
30
Unusual co-occurrence of Evans syndrome and pure red cell aplasia in elderly patient with prostate cancer. ( 27465154 )
2016
31
Invasive Thymoma with Pure Red Cell Aplasia and Amegakaryocytic Thrombocytopenia. ( 28053696 )
2016
32
TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib. ( 27843612 )
2016
33
Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab. ( 27408396 )
2016
34
Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation. ( 27642338 )
2016
35
Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study. ( 26708119 )
2016
36
Epoetin-I^ induced pure red cell aplasia: an unintended consequence. ( 27932518 )
2016
37
Simultaneous occurrence of autoimmune hemolytic anemia and pure red cell aplasia. ( 28090019 )
2016
38
Pure red cell aplasia. ( 27913462 )
2016
39
Dapsone-induced pure red cell aplasia and cholestatic jaundice: A new experience for diagnosis and management. ( 27512715 )
2016
40
Monoclonal gammopathy-associated pure red cell aplasia. ( 26999424 )
2016
41
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. ( 26921820 )
2016
42
Holoprosencephaly and Pure Red Cell Aplasia in a Feline Leukaemia Virus-Positive Kitten. ( 26897097 )
2016
43
A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02. ( 27348021 )
2016
44
Successful high-dose dexamethasone treatment of acquired pure red cell aplasia following ABO major mismatched allogeneic hematopoietic stem cell transplantation. ( 27384857 )
2016
45
Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus. ( 27338269 )
2016
46
Pure Red Cell Aplasia Following Interleukin-2 Therapy. ( 27144182 )
2016
47
Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab. ( 27382560 )
2016
48
Pure red cell aplasia. ( 27881371 )
2016
49
Pure red cell aplasia revealing nonnodal mantle cell lymphoma. ( 27322005 )
2016
50
Post renal transplant pure red cell aplasia-is tacrolimus a culprit? ( 27478605 )
2016

Variations for Pure Red-Cell Aplasia

Expression for Pure Red-Cell Aplasia

Search GEO for disease gene expression data for Pure Red-Cell Aplasia.

Pathways for Pure Red-Cell Aplasia

Pathways related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 HLA-A HLA-B HLA-DRB1 IL2 IL2RA STAT3
2
Show member pathways
12.73 EPO HLA-A HLA-B IL2 IL2RA
3 12.65 EPO IL2 IL2RA STAT3
4
Show member pathways
12.62 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
5
Show member pathways
12.43 HLA-DRB1 IL2 IL2RA TRB
6
Show member pathways
12.32 HLA-A HLA-B HLA-DRB1 IL2 IL2RA STAT3
7
Show member pathways
12.26 HLA-DRB1 IL2 IL2RA STAT3 TRB
8 12.11 HLA-A HLA-B STAT3
9
Show member pathways
12.11 EPO IL2 IL2RA STAT3
10 12.07 HLA-A HLA-B HLA-DRB1 STAT3
11 12.06 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
12
Show member pathways
11.97 HLA-A HLA-B IL2
13 11.96 HLA-A HLA-B HLA-DRB1
14 11.94 HLA-A HLA-B HLA-DRB1
15
Show member pathways
11.89 IL2 IL2RA STAT3
16
Show member pathways
11.84 IL2 IL2RA STAT3
17 11.8 EPO IL2 IL2RA
18 11.72 EPO STAT3 TF
19 11.7 EPO HLA-DRB1 IL2RA
20 11.61 EPO IL2 IL2RA STAT3
21
Show member pathways
11.46 HLA-A IL2 IL2RA
22 11.16 IL2 IL2RA
23
Show member pathways
11.15 HLA-A HLA-DRB1 IL2 IL2RA STAT3 TRB
24 11.12 IL2 TRB
25 11.02 HLA-A HLA-B
26 11.02 HLA-DRB1 IL2 TRB
27 11.01 IL2RA STAT3
28 10.7 HLA-DRB1 IL2 IL2RA STAT3

GO Terms for Pure Red-Cell Aplasia

Cellular components related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 9.33 HLA-A HLA-B HLA-DRB1
2 MHC class I protein complex GO:0042612 9.26 HLA-A HLA-B
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-A HLA-B HLA-DRB1
4 cell surface GO:0009986 9.1 EPO HLA-A HLA-B HLA-DRB1 IL2RA TF

Biological processes related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 ALB EPO IL2 STAT3
2 viral process GO:0016032 9.84 HLA-A HLA-B HLA-DRB1 STAT3
3 immune system process GO:0002376 9.72 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
4 immune response GO:0006955 9.65 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
5 interferon-gamma-mediated signaling pathway GO:0060333 9.63 HLA-A HLA-B HLA-DRB1
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 EPO IL2 STAT3
7 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.56 HLA-A HLA-B
8 positive regulation of T cell differentiation GO:0045582 9.52 IL2 IL2RA
9 regulation of regulatory T cell differentiation GO:0045589 9.51 IL2 IL2RA
10 inflammatory response to antigenic stimulus GO:0002437 9.49 HLA-DRB1 IL2RA
11 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.48 HLA-A HLA-B
12 negative regulation of lymphocyte proliferation GO:0050672 9.4 IL2 IL2RA
13 protection from natural killer cell mediated cytotoxicity GO:0042270 9.37 HLA-A HLA-B
14 antigen processing and presentation GO:0019882 9.33 HLA-A HLA-B HLA-DRB1
15 regulation of T cell homeostatic proliferation GO:0046013 8.96 IL2 IL2RA
16 positive regulation of activated T cell proliferation GO:0042104 8.8 EPO IL2 IL2RA

Molecular functions related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.8 HLA-A HLA-B HLA-DRB1

Sources for Pure Red-Cell Aplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....